You are here: Home » PTI Stories » National » News
Business Standard

Dr Reddy's, UCB India join hands to distribute epilepsy drug in India

Press Trust of India  |  New Delhi 

Drug firm today said it has entered in to an agreement with pharma firm for distribution and co-promotion of Briviact, used for treatment of in

The agreement grants Dr Reddy's the exclusive right to distribute Briviact in India, the Hyderabad-based company said in a filing to BSE.

"In our endeavour to make innovative medicines accessible to patients in India, we are excited to with for Briviact, a novel that will make a difference to the lives of patients living with epilepsy," Dr Reddy's Branded Markets (India and Emerging Markets) MV Ramana said.

Briviact (brivaracetam) is approved as an for the treatment of in patients who are 16 years of age and older, the statement said.

"This partnership is another important step towards us providing value together to patients by making Briviact available as an additional treatment choice for epilepsy," Neurology Patient Value Unit Head of International Markets Max Bricchi said.

Shares of today closed at Rs 2,329.80 per scrip on BSE, up 2.80 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, July 09 2018. 16:55 IST